🟢 Cue Biopharma is trading 12% up with no identified company-specific catalyst

Cue Biopharma is trading at $25.00, up 11.96%, with no clear company-specific announcement identified to explain the October 9 move.

• Recent CUE-221 trial results predate this session.
• Biotech ETF XBI is up 2.50%, offering supportive industry context but not establishing the cause of Cue Biopharma’s larger gain.
• Available information does not establish current trading volume or activity level.